Under the Paperwork Reduction Act of 1995, no persons are require

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10599718
Filing Date		2006-10-06
First Named Inventor HUSS		AIN
Art Unit		
Examiner Name		
Attorney Docket Number		SMB-1010

				U.S.	PATENTS	Remove	
Examiner Initial*			Kind Code <sup>1</sup>			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	6013173	B1	2000-01-11	BOGDAN	col. 2 lines 55-67; col. 7 lines 38-48 col.8 lines 8-28	
2 604844		6048449	B1 2000-04-11 B0		BOGDAN	ool. 2 line 56 - col. 3 line 10; col. 5 lines 47-53; col. 7 lines 38-56	
	3	4060498 B1 1977-11-29 KAV		KAWAGOSHI et al.	whole document		
	4	6103660	B1 2000-08-15 VAN YPEREN		VAN YPEREN	col. 2 lines 42-54; col. 3 lines 17-27 claims	
	5	4456703	B1	1984-06-26	ALDRIDGE	whole document	
	6	5100857	B1	1992-03-31	SATO et al.	whole document	
	7	5714092	B1	1998-02-03	VAN LOOIJ et al.	col. 3 line 62-col. 4 line5	
If you wis	h to a	dd additional U.S. Pa	tent citatio	ı n information p	lease click the Add button.	Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10599718
Filing Date			2006-10-06
	First Named Inventor	HUSS	SAIN
	Art Unit		
	Examiner Name		
	Attack Desirat North	or	CMD 1010

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Pate		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wish	n to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information	please click the Ad	d butto	on. Add	
				FORE	GN PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	2196349	CA		B1	1997-08-01	CHEUNG et al.		p. 2 lines 14-19; p.3 lines 14-19; claims 1 and 4	
	2	WO 02 089978			A1	2002-11-14	HU et al.		p.3 lines 20-25; p.7 line 15 - p. 9 line 13; p. 13 lines 9 -15; p. 14 lines 1-8; examples 1-4; claims	
	3	1196907	CA		B1	1985-11-19	SAMBROOK et al.		p. 2c; p.2d; pp. 7-8; claims	
	4	2359940	CA		A1	2000-07-27	DUNLEAVY et al.		p.1 lines 18-33; p. 2 line 31 to p. 3 line 10; examples; claims	
If you wish	n to a	dd additional Foreign F	atent Do	cument	citation	information p	lease click the Add	butto	n Add	
			NON	I-PATEI	NT LITE	ERATURE DO	CUMENTS		Remove	
	Examiner   Cite   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, ctly andor country where published.					Тs				
	1									

#### 

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

16e Kin Codes of USPTO Patert Documents at www.USPTO.GOV or MPEP 801.04. 2 Enter office that issued the document, by the hoveletic code (WIPO Standard S13.) 3 "For implantee patent documents, the included on the year of the import on improved the Empirical represents the serial running of the Empirical represents the serial running of the Empirical represents the serial running of the Empirical Running of the Empirica

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10599718		
Filing Date		2006-10-06		
First Named Inventor	HUSS	HUSSAIN		
Art Unit				
Examiner Name				
Attorney Docket Number		SMR-1010		

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 97 CFR 137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 137(c)(c)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

\_ ...

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/John M. Hammond/	Date (YYYY-MM-DD)	2007-03-19
Name/Print	John M. Hammond	Registration Number	52.986

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1450, Alexandria, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1450, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.